On a relative basis, the stock has outperformed the S&P 500 by 4.29% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.18% in the last 1 week, and is up 11.34% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Alexion Pharmaceuticals (NASDAQ:ALXN): The stock opened at $127.74 on Friday but the bulls could not build on the opening and the stock topped out at $127.98 for the day. The stock traded down to $125.34 during the day, due to lack of any buying support eventually closed down at $125.80 with a loss of -1.18% for the day. The stock had closed at $127.30 on the previous day. The total traded volume was 1,381,823 shares.
The stock has recorded a 20-day Moving Average of 3.62% and the 50-Day Moving Average is 5.1%. Alexion Pharmaceuticals, Inc. has dropped 20.93% during the last 3-month period . Year-to-Date the stock performance stands at -34.05%.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.